Treating all patients would increase the annual prescription costs, €3.9 million for SGLT2i and €10.4 million for GLP-1 RA.<h4>Conclusion</h4>SGLT2i and GLP-1 RA were underutilised in patients with coexisting IHD and T2D. Here, GLP1R is linked to type 2 diabetes mellitus.